Laird Norton Wetherby Wealth Management’s Genomic Health, Inc. GHDX Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-9,219	Closed	-$296K	–	679
2017 Q3	$296K	Buy	9,219 +307	+3%	+$9.68K	0.04%	462
2017 Q2	$290K	Buy	8,912 +317	+4%	+$10K	0.05%	442
2017 Q1	$271K	Buy	8,595 +340	+4%	+$10.1K	0.05%	453
2016 Q4	$243K	Buy	8,255 +345	+4%	+$10.5K	0.05%	459
2016 Q3	$229K	Buy	+7,910	New	+$220K	0.05%	461
2016 Q1	–	Sell	-6,819	Closed	-$240K	–	504
2015 Q4	$240K	Buy	+6,819	New	+$183K	0.06%	374

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's GHDX Position: Q4 2017 in Review

Laird Norton Wetherby Wealth Management sold out of Genomic Health, Inc. (GHDX) in Q4 2017, closing a stake of 9,219 shares — an estimated $296K sold.

Laird Norton Wetherby Wealth Management first reported a position in GHDX in Q4 2015 and held it in 6 quarters. The position peaked at $296K in Q3 2017. 135 funds tracked by Wall St. Rank hold GHDX as of Q4 2017.

Laird Norton Wetherby Wealth Management reported no remaining Genomic Health, Inc. position as of Q4 2017 after selling out during the quarter.
Laird Norton Wetherby Wealth Management sold 9,219 Genomic Health, Inc. shares in Q4 2017, an estimated $296K.
Laird Norton Wetherby Wealth Management first reported a position in Genomic Health, Inc. in Q4 2015 and held it in 6 quarters.
Laird Norton Wetherby Wealth Management's Genomic Health, Inc. position peaked at $296K in Q3 2017.
135 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2017.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q4 2017, filed 9 Feb 2018.